Navigation Links
Biocept to Present at Molecular Medicine Tri-Con 2016
Date:3/3/2016

SAN DIEGO, March 3, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that Veena Singh, MD, Biocept's Senior Vice President and Senior Medical Director, will present "Ultra-Sensitive CTC Analysis in the Management of Cancer" on Monday, March 7th, and will participate in a panel discussion focused on the use of circulating tumor cell (CTC) in liquid biopsy on Wednesday, March 9th, at the Molecular Medicine Tri-Con 2016 meeting being held in San Francisco.

"First generation CTC detection systems were designed to capture only cells expressing an antigen found on epithelial tumor cells, known as EpCAM.  These approaches miss non-EpCAM expressing types of tumor cells, such as those with mesenchymal or stem cell properties, that can contain important tumor related information," said Dr. Singh. "At Biocept, we have developed a highly sensitive approach that can detect a broader spectrum of CTCs and simultaneously identify actionable biomarker alterations within these cells.  Our assays detect results that could be missed by relying solely on interrogating a subset of CTCs and provide additional information that physicians can use when making treatment decisions.

"The proprietary platforms we have developed at Biocept allows for liquid biopsy assays that utilize both CTCs and circulating tumor DNA (ctDNA) for both profiling and monitoring patients with solid tumors," continued Dr. Singh.  "We appreciate the opportunity to share progress and evidence from our real-world experience with scientific leaders attending this prestigious industry conference.  Much of this conference is dedicated to liquid biopsy, which indicates a growing level of interest in our field among researchers, clinicians and the biopharma industry in general."

About the Molecular Medicine Tri-Con
The 23rd Annual Molecular Medicine Tri-Con conference is a diverse event, focusing on molecular medicine, specifically on discovery, genomics, diagnostics and information technology.  The Tri-Conference is the largest annual conference bringing together the world's most influential diagnostic experts.  This year's conference is projected to attract more than 3,300 diagnostics experts from more than 40 countries. The conference will be held March 6-11, 2016, at the Moscone North Convention Center in San Francisco. To learn more, visit http://www.triconference.com.

About Biocept

Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept's technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers testing for gastric, breast, prostate, colon and lung cancers as well as melanoma and plans to introduce CLIA-validated tests for colorectal cancer, prostate cancer and other solid tumors in the near term.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to the potential of our diagnostic assays to improve the detection and treatment of cancer, the growing level of interest in liquid biopsy, and our ability to introduce CLIA-validated tests in the future, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO

 


'/>"/>
SOURCE Biocept, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Biocept Secures Agreement with Preferred Provider Organization Prime Health Services
2. Data Demonstrating Extremely High Sensitivity of Biocepts Blood-Based Liquid Biopsy in Detecting Lung Cancer Mutations Presented at UCSD Moores Cancer Center Translational Oncology Symposium
3. Biocept CEO Michael W. Nall to Present at the Personalized Medicine World Conference
4. Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer
5. Biocept Announces Collaboration with Baylor College of Medicine to Develop Liquid Biopsy Tests for Estrogen Receptor Gene
6. Biocept Expands Patent Protection in Europe
7. Biocept Reports Third Quarter 2015 Financial Results
8. Biocept to Hold 2015 Third Quarter Conference Call on November 5
9. Aratana Therapeutics to Present at Barclays Healthcare Conference
10. Ambry Genetics to Present Seven Abstracts at Upcoming ACMG Annual Clinical Genetics Meeting
11. Immunexpress Announces Presentation at the 36th International Symposium on Intensive Care and Emergency Medicine on the Need for an Objective Diagnostic Tool for Systemic Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Sciences today announced the three Winners and six Finalists of the 2017 Blavatnik ... annually by the Blavatnik Family Foundation and administered by the New York Academy ...
(Date:10/12/2017)... ... ... AMRI, a global contract research, development and manufacturing organization ... quality of life, will now be offering its impurity solutions as a stand-alone ... for all new drug products, including the finalization of ICH M7 earlier this ...
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply for ... time. So which eye do you rinse first if a dangerous substance enters both eyes? ... Eye Wash with its unique dual eye piece. , “Whether its dirt and debris, ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
Breaking Biology Technology:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
Breaking Biology News(10 mins):